Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate a Connection between Pore Formation and Cytotoxicity

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Prangkio, Panchika ^a   Yusko, Erik C ^a   Sept, David ^a   Yang, Jerry ^b   Mayer, Michael ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; DIMER; MONOMER; OLIGOMER;

ARTICLE; BETA SHEET; CHANNEL GATING; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); CYTOTOXICITY; FLUORESCENCE; LIPID BILAYER; MULTIVARIATE ANALYSIS; PARTIAL LEAST SQUARES REGRESSION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CROSS LINKING; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL MEMBRANE; HUMANS; MODELS, MOLECULAR; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; NEURONS; PEPTIDE FRAGMENTS; PORE FORMING CYTOTOXIC PROTEINS; PROTEIN STRUCTURE, SECONDARY;

EID: 84867492819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047261     Document Type: Article

References (114)

1. Selkoe DJ, (1991) The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
2. Hardy JA, Higgins GA, (1992) Alzheimer's disease- the amyloid cascade hypothesis. Science 256: 184-185.
3. LaFerla FM, Green KN, Oddo S, (2007) Intracellular amyloid-β in Alzheimer's disease. Nature Reviews Neuroscience 8: 499-509.
4. Glenner GG, Wong CW, (1984) Alzheimer's disease- initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 120: 885-890.
5. Wong CW, Quaranta V, Glenner GG, (1985) Neuritic plaques and cerebrovascular amyloid in Alzheimer's disease are antigenically related. Proceedings of the National Academy of Sciences of the United States of America 82: 8729-8732.
6. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
7. Mattson MP, (2004) Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
8. Rangachari V, Reed DK, Moore BD, Rosenberry TL, (2006) Secondary structure and interfacial aggregation of amyloid-β(1-40) on sodium dodecyl sulfate micelles. Biochemistry 45: 8639-8648.
9. Querfurth HW, LaFerla FM, (2010) Mechanisms of disease: Alzheimer's disease. New England Journal of Medicine 362: 329-344.
10. Parihar MS, Hemnani T, (2004) Alzheimer's disease pathogenesis and therapeutic interventions. Journal of Clinical Neuroscience 11: 456-467.
11. Habib LK, Lee MTC, Yang J, (2010) Inhibitors of catalase-amyloid interactions protect cells from β-amyloid-induced oxidative stress and toxicity. Journal of Biological Chemistry 285: 38933-38943.
12. Eisenberg D, Jucker M, (2012) The amyloid state of proteins in human diseases. Cell 148: 1188-1203.
13. Lansbury PT, Lashuel HA, (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443: 774-779.
14. Selkoe DJ, (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine 17: 1060-1065.
15. Walsh DM, Selkoe DJ, (2007) Aβ Oligomers- a decade of discovery. Journal of Neurochemistry 101: 1172-1184.
16. Gong YS, Chang L, Viola KL, Lacor PN, Lambert MP, et al. (2003) Alzheimer's disease-affected brain: presence of oligomeric Β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 100: 10417-10422.
17. LaFerla FM, (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nature Reviews Neuroscience 3: 862-872.
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ(1-42) are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95: 6448-6453.
19. Small DH, Mok SS, Bornstein JC, (2001) Alzheimer's disease and Aβ toxicity: from top to bottom. Nature Reviews Neuroscience 2: 595-598.
20. Turner PR, O'Connor K, Tate WP, Abraham WC, (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Progress in Neurobiology 70: 1-32.
21. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511.
22. Khachaturian ZS, (1987) Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiology of Aging 8: 345-346.
23. Ono K, Condron MM, Teplow DB, (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proceedings of the National Academy of Sciences of the United States of America 106: 14745-14750.
24. Demuro A, Mina E, Kayed R, Milton SC, Parker I, et al. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Journal of Biological Chemistry 280: 17294-17300.
25. Holtzman DM, Goate A, Kelly J, Sperling R (2011) Mapping the road forward in Alzheimer's disease. Science Translational Medicine 3.
26. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW, (1993) Neurodegeneration induced by β-amyloid peptides in vitro- the role of peptide assembly state. Journal of Neuroscience 13: 1676-1687.
27. Broersen K, Rousseau F, Schymkowitz J, (2010) The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res Ther 2: 12.
28. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, et al. (2008) Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. Journal of Neuroscience 28: 4231-4237.
29. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, et al. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiology of Disease 36: 293-302.
30. Shankar GM, Li SM, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 14: 837-842.
31. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, et al. (2010) Amyloid β-protein dimers rapidly form stable synaptotoxic protofibrils. Journal of Neuroscience 30: 14411-14419.
32. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, et al. (1995) Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. Journal of Biological Chemistry 270: 9564-9570.
33. Jin M, Shepardson N, Yang T, Chen G, Walsh D, et al. (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America 108: 5819-5824.
34. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, et al. (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature advance online publication. doi:10.1038/nature11060.
35. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ, (2006) Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. Journal of Physiology 572: 477-492.
36. Viola KL, Velasco PT, Klein WL, (2008) Why Alzheimer's is a disease of memory: the attack on synapses by Aβ oligomers (ADDLs). Journal of Nutrition Health & Aging 12: 51S-57S.
37. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Aβ. Journal of Neurochemistry 100: 23-35.
38. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, et al. (2006) Solution state characterization of amyloid β-derived diffusible ligands. Biochemistry 45: 15157-15167.
39. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nature Chemistry 1: 326-331.
40. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
41. Harper JD, Wong SS, Lieber CM, Lansbury PT, (1997) Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chemistry & Biology 4: 119-125.
42. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB, (1997) Amyloid β-protein fibrillogenesis- detection of a protofibrillar intermediate. Journal of Biological Chemistry 272: 22364-22372.
43. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, et al. (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. Journal of Biological Chemistry 284: 4230-4237.
44. Demuro A, Smith M, Parker I, (2011) Single-channel Ca2+ imaging implicates Aβ1-42 amyloid pores in Alzheimer's disease pathology. Journal of Cell Biology 195: 515-524.
45. Puzzo D, Arancio O, (2006) Fibrillar β-amyloid impairs the late phase of long term potentiation. Current Alzheimer Research 3: 179-183.
46. Lorenzo A, Yuan ML, Zhang ZH, Paganetti PA, Sturchler-Pierrat C, et al. (2000) Amyloid β interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nature Neuroscience 3: 460-464.
47. Chen QS, Kagan BL, Hirakura Y, Xie CW, (2000) Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides. Journal of Neuroscience Research 60: 65-72.
48. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's disease-associated amyloid β-protein is an antimicrobial peptide. PLoS ONE 5.
49. Williams TL, Serpell LC, (2011) Membrane and surface interactions of Alzheimer's Aβ peptide- Insights into the mechanism of cytotoxicity. FEBS Journal 278: 3905-3917.
50. Wong PT, Schauerte JA, Wisser KC, Ding H, Lee EL, et al. (2009) Amyloid-β membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. Journal of Molecular Biology 386: 81-96.
51. Arispe N, Pollard HB, Rojas E, (1993) Giant multilevel cation channels formed by Alzheimer-disease amyloid beta-protein [Aβ-P(1-40)] in bilayer membranes. Proceedings of the National Academy of Sciences of the United States of America 90: 10573-10577.
52. Jang H, Zheng J, Nussinov R, (2007) Models of β-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. Biophysical Journal 93: 1938-1949.
53. Kagan BL, Azimov R, Azimova R, (2004) Amyloid peptide channels. Journal of Membrane Biology 202: 1-10.
54. Capone R, Quiroz FG, Prangkio P, Saluja I, Sauer AM, et al. (2009) Amyloid-β-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotoxicity Research 16: 1-13.
55. Caughey B, Lansbury PT, (2003) Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience 26: 267-298.
56. Lal R, Lin H, Quist AP, (2007) Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochimica Et Biophysica Acta-Biomembranes 1768: 1966-1975.
57. Arispe N, Diaz JC, Simakova O, (2007) Aβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers. Biochimica Et Biophysica Acta-Biomembranes 1768: 1952-1965.
58. Kawahara M, (2010) Neurotoxicity of β-amyloid protein: oligomerization, channel formation and calcium dyshomeostasis. Current Pharmaceutical Design 16: 2779-2789.
59. Hartley DM, Walsh DM, Ye CPP, Diehl T, Vasquez S, et al. (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. Journal of Neuroscience 19: 8876-8884.
60. Jang H, Arce FT, Capone R, Ramachandran S, Lal R, et al. (2009) Misfolded amyloid ion channels present mobile β-sheet subunits in contrast to conventional ion channels. Biophysical Journal 97: 3029-3037.
61. Quist A, Doudevski I, Lin H, Azimova R, Ng D, et al. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proceedings of the National Academy of Sciences of the United States of America 102: 10427-10432.
62. Lin H, Bhatia R, Lal R, (2001) Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology Faseb Journal. 15: 2433-2444.
63. Strodel B, Lee JWL, Whittleston CS, Wales DJ, (2010) Transmembrane structures for Alzheimer's Aβ(1-42) oligomers. Journal of the American Chemical Society 132: 13300-13312.
64. Shafrir Y, Durell S, Arispe N, Guy HR, (2010) Models of membrane-bound Alzheimer's Abeta peptide assemblies. Proteins-Structure Function and Bioinformatics 78: 3473-3487.
65. Pan J, Han J, Borchers CH, Konermann L, (2012) Structure and dynamics of small soluble Aβ(1-40) oligomers studied by top-down hydrogen exchange mass spectrometry. Biochemistry 51: 3694-3703.
66. Schauerte JA, Wong PT, Wisser KC, Ding H, Steel DG, et al. (2010) Simultaneous single-molecule fluorescence and conductivity studies reveal distinct classes of Aβ species on lipid bilayers. Biochemistry 49: 3031-3039.
67. Benilova I, Karran E, De Strooper B, (2012) The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nature Neuroscience 15: 349-357.
68. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, et al. (2012) Atomic view of a toxic amyloid small oligomer. Science 335: 1228-1231.
69. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, (2002) Neurodegenerative disease- amyloid pores from pathogenic mutations. Nature 418: 291-291.
70. Stroud JC, Liu C, Teng PK, Eisenberg D (2012) Toxic fibrillar oligomers of amyloid-β have cross-β structure. Proceedings of the National Academy of Sciences of the United States of America.
71. Arispe N, Rojas E, Pollard HB, (1993) Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proceedings of the National Academy of Sciences of the United States of America 90: 567-571.
72. Bhatia R, Lin H, Lal R, (2000) Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. FASEB Journal 14: 1233-1243.
73. Hirakura Y, Lin MC, Kagan BL, (1999) Alzheimer amyloid Aβ1-42 channels: effects of solvent, pH, and Congo Red. Journal of Neuroscience Research 57: 458-466.
74. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC, (2002) The channel hypothesis of Alzheimer's disease: current status. Peptides 23: 1311-1315.
75. Kourie J, Henry C, Farrelly P, (2001) Diversity of amyloid β protein fragment [1-40]-formed channels. Cellular and Molecular Neurobiology 21: 255-284.
76. Micelli S, Meleleo D, Picciarelli V, Gallucci E, (2004) Effect of sterols on β-amyloid peptide (AβP 1-40) channel formation and their properties in planar lipid membranes. Biophysical Journal 86: 2231-2237.
77. Arispe N, Pollard HB, Rojas E, (1996) Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proceedings of the National Academy of Sciences of the United States of America 93: 1710-1715.
78. Kawahara M, Arispe N, Kuroda Y, Rojas E, (1997) Alzheimer's disease amyloid beta-protein forms Zn2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophysical Journal 73: 67-75.
79. Kagan BL, (2012) Membrane pores in the pathogenesis of neurodegenerative disease. Progress in molecular biology and translational science 107: 295-325.
80. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, et al. (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. Nature Chemical Biology 6: 140-147.
81. Majd S, Yusko EC, Billeh YN, Macrae MX, Yang J, et al. (2010) Applications of biological pores in nanomedicine, sensing, and nanoelectronics. Current Opinion in Biotechnology 21: 439-476.
82. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, et al. (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. Journal of Neuroscience 25: 1071-1080.
83. Ryan DA, Narrow WC, Federoff HJ, Bowers WJ, (2010) An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. Journal of Neuroscience Methods 190: 171-179.
84. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, et al. (2011) Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun 2: 336.
85. Bitan G, Lomakin A, Teplow DB, (2001) Amyloid β-protein oligomerization- prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. Journal of Biological Chemistry 276: 35176-35184.
86. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, et al. (1994) Secondary structure of amyloid-βpeptide correlates with neurotoxic activity in vitro. Molecular Pharmacology 45: 373-379.
87. Boulesteix A-L, Strimmer K, (2007) Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Briefings in Bioinformatics 8: 32-44.
88. Krishnan A, Williams LJ, McIntosh AR, Abdi H, (2011) Partial least squares (PLS) methods for neuroimaging: a tutorial and review. Neuroimage 56: 455-475.
89. Rajalahti T, Kvalheim OM, (2011) Multivariate data analysis in pharmaceutics: a tutorial review. International Journal of Pharmaceutics 417: 280-290.
90. Shao J, Tu D (1995) The jackknife and bootstrap. New York: Springer.
91. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, et al. (2009) β-amyloid monomers are neuroprotective. Journal of Neuroscience 29: 10582-10587.
92. Baruch-Suchodolsky R, Fischer B, (2009) Aβ40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 48: 4354-4370.
93. Lin MCA, Kagan BL, (2002) Electrophysiologic properties of channels induced by A beta 25-35 in planar lipid bilayers. Peptides 23: 1215-1228.
94. Johnson RD, Schauerte JA, Wisser KC, Gafni A, Steel DG (2011) Direct observation of single amyloid-β(1-40) oligomers on live cells: binding and growth at physiological concentrations. PLoS ONE 6.
95. Lashuel HA, Lansbury PT, (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Quarterly Reviews of Biophysics 39: 167-201.
96. Kagan BL, Jang H, Capone R, Arce FT, Ramachandran S, et al. (2012) Antimicrobial properties of amyloid peptides. Molecular Pharmaceutics 9: 708-717.
97. Jang H, Arce FT, Ramachandran S, Capone R, Lal R, et al. (2010) beta-Barrel Topology of Alzheimer's beta-Amyloid Ion Channels. Journal of Molecular Biology 404: 917-934.
98. Strodel B, Lee JWL, Whittleston CS, Wales DJ, (2010) Transmembrane Structures for Alzheimer's A beta(1-42) Oligomers. Journal of the American Chemical Society 132: 13300-13312.
99. Connelly L, Jang H, Arce FT, Capone R, Kotler SA, et al. (2012) Atomic Force Microscopy and MD Simulations Reveal Pore-Like Structures of All-D-Enantiomer of Alzheimer's beta-Amyloid Peptide: Relevance to the Ion Channel Mechanism of AD Pathology. Journal of Physical Chemistry B 116: 1728-1735.
100. Jang HB, Zheng J, Lal R, Nussinov R, (2008) New structures help the modeling of toxic amyloid beta ion channels. Trends in Biochemical Sciences 33: 91-100.
101. Sanchez L, Madurga S, Pukala T, Vilaseca M, Lopez-Iglesias C, et al. (2011) Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties. Journal of the American Chemical Society 133: 6505-6508.
102. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, et al. (2003) Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences of the United States of America 100: 330-335.
103. Demuro A, Parker I, Stutzmann GE, (2010) Calcium signaling and amyloid toxicity in Alzheimer's disease. Journal of Biological Chemistry 285: 12463-12468.
104. Butterfield SM, Lashuel HA, (2010) Amyloidogenic protein membrane interactions: mechanistic insight from model systems. Angewandte Chemie-International Edition 49: 5628-5654.
105. Schnabel J, (2011) Amyloid: little proteins, big clues. Nature 475: S12-S14.
106. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB, (2009) Small molecule blockers of the Alzheimer Aβ calcium channel potently protect neurons from Aβ cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 106: 3348-3353.
107. Marx J, (2007) Alzheimer's disease- Fresh evidence points to an old suspect: calcium. Science 318: 384-385.
108. Arispe NJ, Simakova O (2007) Alzheimer's disease AβP peptide binding to cell membranes is correlated to membrane surface phosphatidylserine levels. Biophysical Journal: 612A-612A.
109. Bitan G, Fradinger EA, Spring SM, Teplow DB, (2005) Neurotoxic protein oligomers- what you see is not always what you get. Amyloid-Journal of Protein Folding Disorders 12: 88-95.
110. Ding H, Wong PT, Lee EL, Gafni A, Steel DG, (2009) Determination of the oligomer size of amyloidogenic protein β-amyloid(1-40) by single-molecule spectroscopy. Biophysical Journal 97: 912-921.
111. Kurganov B, Doh M, Arispe N, (2004) Aggregation of liposomes induced by the toxic peptides Alzheimer's Aβs, human amylin and prion (106-126): facilitation by membrane-bound GM1 ganglioside. Peptides 25: 217-232.
112. Mayer M, Semetey V, Gitlin I, Yang J, Whitesides GM, (2008) Using ion channel-forming peptides to quantify protein-ligand interactions. Journal of the American Chemical Society 130: 1453-1465.
113. Hille B (2001) Ion channels of excitable membranes. Sunderland: Sinauer Associates, Inc.
114. Apell HJ, Bamberg E, Lauger P, (1979) Effects of Surface-Charge on the Conductance of the Gramicidin Channel. Biochimica Et Biophysica Acta 552: 369-378.